Answers are grounded in this paper and cite their sources.
This review demonstrates belotecan's therapeutic potential in ovarian cancer, suggesting improved treatments via nano-formulations.
Background Ovarian cancer is a major gynecologic malignancy with high morbidity and mortality rates. Current treatment options have limited long-term effectiveness due to tumor resistance and significant side effects. Main body This article explores the potential of belotecan, a derivative of camptothecin, as a promising therapeutic agent for ovarian cancer. Belotecan’s ability to inhibit topoisomerase I, induce DNA damage, and modulate inflammation positions it as a strong candidate for enhancing ovarian cancer treatment. However, challenges such as poor bioavailability, rapid systemic clearance, and dose-limiting toxicity remain. To overcome these issues, nano-formulation strategies are proposed to improve pharmacokinetics, solubility, and tumor-specific targeting. These strategies may enhance belotecan's stability, increase its therapeutic efficacy, and minimize off-target effects. Conclusion This review provides a detailed examination of belotecan’s molecular mechanisms, its anti-inflammatory and anti-cancer properties, and the advances in nano-formulation technologies. The integration of these strategies could lead to more effective treatments and improved outcomes for ovarian cancer patients.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: